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AbsTrACT 
background/Aims Vascular endothelial growth factor 
(VEGF) is a key player in the pathogenesis of neovascular 
age-related macular degeneration (nAMD) and is also 
involved in the final common pathway of antidepressant 
medication. This study investigated the relationship 
between the need for anti-VEGF retreatment in patients 
with nAMD and antidepressant medication, and the 
potential impact of ocular structural factors.
Methods Data from two identical prospective 2-year 
treatment protocols using ranibizumab or aflibercept in 
a variable-dosing regimen (’Observe-and-Plan’) were 
analysed. Retreatment requirement was compared with 
antidepressant medication intake (primary outcome) 
and a variety of ocular factors from baseline and 
from month 3 response (secondary outcomes), using 
univariate and multivariate analyses.
results Of the 206 included patients (227 eyes), 
19 were on antidepressant medication. Their nAMD 
eyes significantly more often had pigment epithelium 
detachment (PED, p=0.04). Multivariate analysis 
revealed a significant association between anti-VEGF 
retreatment requirement and antidepressant medication 
use (p=0.027), as well as thicker central retinal thickness 
at month 3 (p<0.0001) and month 3 PED height 
(p=0.001).
Conclusion This study provides evidence that treatment 
with antidepressant medication increases the anti-VEGF 
retreatment requirement in patients with nAMD, possibly 
through the interplay of antidepressant medication, 
depression status and VEGF levels.
InTroduCTIon
Age-related macular degeneration (AMD) is the 
leading cause of severe visual loss in people >50 
years old due to neovascular AMD (nAMD) and 
geographic atrophy (GA). nAMD is typically 
treated with repeated intravitreal injections of anti-
vascular endothelial growth factors (anti-VEGF), 
which improve visual outcomes, irrespective of 
using ranibizumab,1 aflibercept2 or bevacizumab.3 
Anti-VEGF treatment has profoundly changed the 
visual prognosis of patients with nAMD. However, 
frequent or chronic reinjections are often needed. 
This retreatment need varies widely between 
patients,4 for unclear reasons, from patients who 
are refractory to the maximal monthly treatments 
due to persistent or recurrent exudative fluid,5 to 
those responding to a regimen with 3-monthly or 
fewer injections, without recurrent exudation.4 6 
The factors associated with anti-VEGF refracto-
riness and the number of anti-VEGF retreatments 
required are poorly understood. Vitreomacular 
adhesion and traction,7 polypoidal choroidal vascu-
lopathy, older age and male sex,8 and untreated 
obstructive sleep apnoea9 may increase recurrence 
risk. The role of genetic polymorphisms8 and 
beta blocker medication10 remains controversial.
Depressive symptoms are present in 20%–24% 
of patients with AMD, particularly early during 
the anti-VEGF treatment.11 Patients with AMD 
might be at risk of developing depression due to 
fear or actual vision loss. On the other hand, depres-
sion and antidepressant medication could influence 
AMD course since there is a strong link among 
depression, its treatment and VEGF levels. Indeed, 
VEGF polymorphisms are risk factors for major 
depressive disorder.12 Furthermore, VEGF and 
VEGF receptor 2 gene expression and VEGF serum 
levels are sometimes reported increased in major 
depressive disorder.13–15 Most crucially, antidepres-
sant response is related to increased VEGF serum 
levels,16 17 and preclinical studies formally demon-
strated the need of a hippocampal VEGF receptor 
activation.18 19 To the best of our knowledge, there 
is no evidence in epidemiological studies for depres-
sion as a risk factor to develop nAMD. As the VEGF 
pathway can be clearly linked to the effect of anti-
depressant medication, but only relatively uncertain 
to the depressive disorder itself, we focused here on 
the use of antidepressant medication.
Thus, we investigated the relationship between 
antidepressant medication and retreatment need 
in an interval-based individualised retreatment 
regimen for nAMD. Second, we investigated 
various ocular and systemic factors that might 
impact retreatment need.
MeThods
Data from two consecutive prospective interven-
tional 2-year studies were used in this post-hoc 
analysis. Both protocols were originally designed to 
investigate the usefulness of the Observe-and-Plan 
regimen, an individually planned, interval-based, 
variable-dosing regimen, using ranibizumab4 or 
aflibercept20 as the anti-VEGF drug for treating 
naïve nAMD. The first study, using ranibizumab,4 
was performed in 2011–2013, and the second 
study, using aflibercept,20 was performed in 2013–
2015, due to the later availability of the drug. The 
Observe-and-Plan regimen (see online supplemen-
tary material) was identical, safe and efficient in 
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both studies. Only eyes that had completed the 2-year study 
protocol were included in the present study.
data collection and image analysis
The following baseline data were collected: age, sex, weight, 
height, history of arterial hypertension, cardiovascular disor-
ders, smoking, medication, in particular antidepressant medica-
tion, and the best corrected visual acuity (BCVA) on the ETDRS 
chart. Information about the depression status was not available.
Imaging data were collected from the baseline multimodal 
imaging, including colour fundus photography (Topcon 
TRC-50IX, Tokyo, Japan), fundus autofluorescence, fluorescein 
angiography and indocyanine green angiography using a Topcon 
TRC-50IX or the Heidelberg Retina Angiograph (Heidelberg 
Engineering, Heidelberg, Germany), and spectral domain optical 
coherence tomography (SD-OCT). The SD-OCT parameters 
included automatic measurements of the central retinal thickness 
(CRT), the presence/absence of intraretinal cysts, the presence/
absence of subretinal fluid, the presence and thickness of the 
subretinal tissue complex, the presence and height of pigment 
epithelium detachment (PED; measured vertical to the Bruch 
membrane, 1:1 µm mode), the subfoveal choroidal thickness, the 
presence of an epiretinal membrane, and the presence of vitreo-
macular adhesion (or traction). Multimodal imaging parameters 
included choroidal neovascular membrane (CNV) type and size 
(measured in disc areas), the presence of soft drusen (determined 
from colour photography), the presence of reticular pseudod-
rusen (determined by infrared and autofluorescence) and the 
presence of GA (defined as a dark zone on fundus autofluores-
cence, increased visibility of the choroidal vessels on fluores-
cein angiography or colour photography, a sharply demarcated 
area with higher reflectivity of the choroid on SD-OCT, and an 
absent retinal pigment epithelium line). The minimum diameter 
of the GA was 250 µm.
The anti-VEGF drug administered and the number of injec-
tions given according to the Observe-and-Plan regimen over the 
2-year period were recorded. The 3-month follow-up parame-
ters were collected and included CRT on SD-OCT, the presence/
absence of intraretinal cysts, the presence/absence of subretinal 
fluid, and the PED height on SD-OCT.
The study-specific characteristics were grouped together, as 
they were invariably linked. The first study used ranibizumab for 
the Observe-and-Plan regimen, the Cirrus SD-OCT (512x126; 
Carl Zeiss Meditec, Oberkochen, Germany) with investigator 
team 1, while the second study used aflibercept for the Observe-
and-Plan regimen, the Heidelberg Spectralis SD-OCT (6 mm, 49 
lines; Heidelberg Engineering, Germany) with investigator team 
2. The same SD-OCT machine was used for each eye throughout 
the respective studies. Therefore, the ‘study’ parameter included 
the drug used, the decision-making team and the SD-OCT 
machine employed.
The primary outcome measure was the influence of antide-
pressant medication on the CNV and the need for retreatment 
with anti-VEGF. The secondary outcome measures were various 
potential factors associated with the retreatment need (number 
of injections), according to univariate and multivariate analyses.
statistical analysis
Descriptive statistics were performed, and univariate and multi-
variate analyses were used to identify risk factors associated 
with the number of anti-VEGF injections required over the 
2-year treatment protocol. Univariate analyses involved Pear-
son’s correlation and analysis of variance for continuous and 
categorical variables, respectively. Stepwise multivariate linear 
regression analysis was performed with the number of anti-
VEGF injections as the dependent variable and factors with a 
p value <0.2 in the univariate analysis. The presence of intra-
retinal or subretinal fluid at month 3 was excluded from multi-
variate analysis, as these directly influence the number of the 
injections, by definition.
For data analysis, a Microsoft Excel V.2010 spreadsheet and 
JMP software for Windows (V.8.0.1, SAS Institute, Cary, North 
Carolina, USA) were used. A two-tailed p value of ≤0.05 was 
considered to indicate statistically significant differences.
resulTs
One hundred and eighty-six patients (205 eyes) completed 
the 2 years of the two prospective Observe-and-Plan trials 
and were included in this post-hoc analysis. The mean age of 
these patients was 79.6 (±7.1) years and 68.1% were female. 
Visual acuity improved from 60.6 (±16.6) ETDRS letters, at 
baseline, by 8.8 (±10.3), 9.3 (±11.9) and 7.7 (±14.6) letters 
by months 3, 12 and 24, respectively. A mean of 14.1 (±5.9) 
injections of either ranibizumab (105 eyes, 51.2%) or aflibercept 
(100 eyes, 48.8%) was used.
Nineteen patients (19 eyes, 9.3%) used antidepressant medi-
cation. The type of antidepressant was a selective serotonine 
reuptake inhibitor in 14 cases, and a norepinephrine/serotonine 
reuptake inhibitor in 5 cases. Patients with antidepressant medi-
cation showed a statistically significantly higher proportion of 
PED ≥200 µm (p=0.01), were more often smokers (p=0.006) 
and less often had the right eye affected (p=0.04). They also 
required non-significantly more retreatment (mean number of 
injections: 16.0 (±6.06)) than patients without antidepressant 
medication (mean number of injections: 13.8 (±5.8)) (p=0.12). 
The baseline and treatment characteristics of the antidepressant 
medication group are summarised in online supplementary table 
1.
The need for retreatment (number of injections over the 
2-year study period) was analysed for various potential ocular 
and systemic factors. Univariate analysis showed significant asso-
ciation between the need for injections and increased PED height 
(p=0.0001) and CRT (p=0.02, corrected for the OCT machine 
used) at baseline. Furthermore, injection need was associated 
with the presence of subretinal (p<0.0001) or intraretinal fluid 
(p=0.001), the PED height (p<0.0001), the CRT (p<0.0001, 
corrected for OCT machine) at month 3, and the study type 
(drug, OCT machine and investigation team; p=0.01). These 
baseline and month 3 parameters were included in multivariate 
analysis (except for the presence of month 3 subretinal/intra-
retinal fluid, as described earlier). Additionally, the amount of 
subretinal fluid at baseline (p=0.10), the presence of depigmen-
tation at baseline (p=0.06), body mass index (p=0.12) and the 
use of antidepressant medication (p=0.12) were included.
A summary is given in table 1. The full version of the univar-
iate analysis is available as online supplementary table 2, 
also including the results with p value >0.2 for the following 
parameters: age, sex, eye, BCVA, the angiographic CNV type, the 
CNV size, intraretinal cysts, subretinal tissue complex, choroidal 
thickness, reticular pseudodrusen, soft drusen, hyperpigmenta-
tion, GA, epiretinal membrane and vitreomacular adhesion at 
baseline, BCVA and BCVA change at month 3, CRT change at 
month 3, arterial hypertension, cardiovascular discorders, and 
smoking history.
The multivariate analysis with the above-mentioned param-
eters led to a final significant model (R2=0.22, p=0.001) 
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Table 1 Summary of the most significant results in univariate 
analysis of the association of ocular and systemic factors with the 
number of anti-VEGF injections required over 2 years of Observe-and-
Plan, an interval-based variable-dosing regimen for neovascular age-
related macular degeneration
Factors n
Mean number 
of anti-VeGF 
injections
Mean±sd P values
  Overall 205 14.1±5.9
  Quartiles 205 10/14/18
ocular baseline characteristics
RPE detachment baseline
  Present ≥200 µm height 57 15.4±0.8 0.054
  Absent or <200 µm height 148 13.6±0.5
  Per 10 µm thickness increase 205 0.09±0.00
(r=0.27)
0.0001*
CRT baseline
  Per 10 µm thickness
  (corrected for study/SD-OCT machine)
205 0.10±0.003
(r=0.22)
0.002*
(0.02*)
Subretinal fluid
  Present 18 14.5±0.46 0.17
  Absent 46 13.1±0.86
  Missing data 1
  Per 10 µm thickness increase 204 0.07±0.004
(r=0.12)
0.10
Depigmentation
  Present 109 13.3±0.56 0.06
  Absent 89 14.9±0.62
ocular follow-up characteristics
Study
  Aflibercept/OCT Spectralis /team 2 100 15.2±0.58 0.01*
  Ranibizumab/OCT Cirrus/team 1 105 13.1±0.56
Type of fluid at month 3
  Subretinal+intraretinal fluid 25 19.5±1.04
  Subretinal fluid only 25 16.9±1.04
  Intraretinal fluid only 91 14.1±0.55 <0.0001*
  No subretinal or intraretinal fluid 64 11.0±0.65
Subretinal fluid at month 3
  Present 50 18.2±0.76 <0.0001*
  Absent 155 12.8±0.43
Intraretinal fluid at month 3
  Present 116 15.3±0.53
  Absent 89 12.6±0.61 0.001*
RPE detachment at month 3
  Per 10 µm thickness 205 0.12±0.003 
(r=0.27)
<0.0001*
CRT at month 3
  Per 10 µm thickness
  (corrected for study/OCT machine)
205 0.36±0.006
(r=0.38)
<0.0001*
(<0.0001*)
systemic characteristics
BMI (kg/m2)
  Per unit 189 −0.13±0.09
(r=−0.11)
0.12
Antidepressant medication
  Yes 19 13.8±0.43
  No 184 16.0±1.33 0.12
  Missing data 2
*P<0.05.
Anti-VEGF, antivascular endothelial growth factor; BMI, body mass index; CRT, 
central retinal thickness; RPE, retinal pigment epithelium; SD-OCT,  spectral 
domain optical coherence tomography.
Table 2 Multivariate regression analysis to identify factors 
associated with the number of injections needed during 2 years 
of anti-VEGF treatment for neovascular age-related macular 
degeneration
Characteristics
unstandardised 
coefficient (se) P values
CRT at month 3 0.03 (0.007) <0.0001*
PED at month 3 0.009 (0.003) 0.0014*
Antidepressant medication 1.50 (0.67) 0.027*
BMI −0.13 (0.08) 0.11
Study/drug type/OCT machine 0.45 (0.40) 0.26
Anti-VEGF,  antivascular endothelial growth factor; BMI, body mass index; CRT, 
central retinal thickness; PED, pigment epithelium detachment; OCT, optical 
coherence tomography.
that included month 3 CRT (corrected for the OCT machine/
study, p<0.0001), month 3 PED height (p=0.0014) and the 
intake of antidepressant medication (p=0.027) (table 2).
dIsCussIon
We here investigated systemic and ocular anatomical factors 
associated with the variable need for anti-VEGF retreatment. 
Multivariate analysis showed a significant association of the 
anti-VEGF retreatment need with antidepressant medication, 
month 3 CRT and month 3 PED height. The role of antide-
pressant medication was not significant in the univariate anal-
ysis, probably because of major differences in the groups (online 
supplementary table 1).
Previous reports have described a strong relationship between 
antidepressant response and VEGF, and its receptor activation in 
the hippocampus.16–18 Patients with major depressive disorder, 
presumably on antidepressant treatment, show higher serum 
VEGF levels.21 22 Since choroidal neovessels are directly in 
contact with the serum and since the retina is part of the central 
nervous system, we hypothesised that a depression and/or anti-
depressant-related VEGF increase might influence exudative 
activity in nAMD and increase the anti-VEGF treatment need. 
A higher anti-VEGF treatment need was associated with anti-
depressant medication use, despite the few patients on antide-
pressant medication (n=19, 9.3% of eyes) in our multivariate 
analysis (p=0.027).
This finding is new, but is consistent with those of previous 
reports. VEGF serum levels and gene expression are impli-
cated in major depressive disorder.13–15 Preclinical research has 
conclusively demonstrated the pivotal role of VEGF in antide-
pressant treatment. VEGF expression is induced by numerous 
classes of antidepressants,16 and VEGF signalling through the 
Flk-1 receptor is required for both antidepressant-induced cell 
proliferation and for an antidepressant behavioural response.16 
Greene et al18 confirmed that the antidepressant effect of fluox-
etine in rats could be blocked by pharmacological inhibition 
of VEGF receptor signalling. Furthermore, chronic fluoxetine 
administration increased VEGF expression in both hippocampal 
neurons and endothelial cells.18 Lee et al19 also showed that 
specific knockdown of VEGF in hippocampal dentate gyrus cells 
inhibited antidepressant-like behaviour in mice. The antidepres-
sant effect of regular exercise in chronically stressed mice is also 
VEGF-mediated and could be abrogated by an inhibitor of the 
VEGF receptor Flk-1.17 
Moreover, a clinical pilot study by Ibrahim et al21 reported 
that the antidepressant effect of sleep deprivation in patients 
with major depressive disorder correlated with increasing VEGF 
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levels. In a prospective controlled trial using duloxetine as anti-
depressant medication, circulating VEGF levels increased in the 
early responder group, but decreased in the early non-responder 
group.22 The antidepressant effect appears to be mediated by 
hippocampal VEGF receptors.16–18 
In nAMD, local VEGF production induces choroidal neovas-
cular growth and exudation. Exudative signs are used as the 
retreatment criterion. The critical VEGF concentration might 
be reached earlier by increased circulating VEGF or locally 
produced VEGF due to antidepressant exposure. This might 
lead to a greater number of injections per time period.
However, in terms of visual function, there was no difference 
between patients on antidepressant medication or not (online 
supplementary table 1). Apparently, the influence of antide-
pressant medication on the VEGF pathway can be effectively 
compensated by the eye-specific adjustment of the retreatment 
frequency according to the exudative signs.
Additionally, our results implicated the CRT and the PED 
height at month 3. A thicker retina is usually associated with the 
presence of fluid and a greater retreatment need, although not 
directly linked to the retreatment protocol. PED is found in a 
high percentage of refractory nAMD.23 
The factors identified in this study explain only some of the 
treatment need variability. Our multifactorial model, although 
statistically significant, remains incomplete (R2=0.22), impli-
cating other as yet unidentified factors.
Previously described factors, such as vitreomacular adhesion 
and traction,7 older age, and male sex,8 were not confirmed 
in our study. Polypoidal choroidal vasculopathy, reported to 
increase the need for retreatment,8 was not included in our 
study. Additionally, we did not include sufficient information 
on obstructive sleep apnoea9 or genetic polymorphisms for 
analysis.8 
Recently, we found that macular atrophy was more frequent 
in patients needing fewer injections.24 This suggests a change 
during the treatment course, from the pure neovascular form to 
some atrophic changes, occurring with reduced VEGF produc-
tion and a lower retreatment need. However, the presence of GA 
at baseline was not associated with the treatment requirement.
Interestingly, the anti-VEGF drug (aflibercept or ranibizumab) 
did not influence the number of treatment sessions. However, 
this parameter was invariably linked to the study, the team and 
the OCT machine used, and these grouped parameters were 
associated with an increased treatment need in the study using 
aflibercept and the Spectralis SD-OCT, perhaps due to the high 
sensitivity of the Heidelberg Spectralis. The parameter per se lost 
significance in the multivariate model.
The study was limited in that it was not prospectively designed. 
We compensated for using different OCT machines by using the 
study team/anti-VEGF drug/OCT machine parameter for anal-
ysis correction. Few patients were on antidepressant medication, 
and current psychiatric diagnosis and depression intensity were 
unknown.
In conclusion, this study provided evidence that antidepres-
sant medication influences anti-VEGF treatment requirement 
in patients with nAMD, possibly via the pro-VEGF effect of 
the medication, and/or depression status. Because AMD is 
frequently associated with depressive symptoms and thus poten-
tially with antidepressant therapy,11 further studies are needed 
to confirm the role of antidepressants in the management of 
patients with nAMD. Furthermore, we described the presence 
and height of PED and a thicker CRT as factors predicting 
higher anti-VEGF treatment requirements in nAMD. Additional 
factors, both systemic and ocular, that may explain the major 
differences in anti-VEGF treatment requirement between indi-
viduals/eyes with nAMD should be identified.
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